Search results
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
Zacks via Yahoo Finance· 2 years agoAstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma...
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
Zacks via Yahoo Finance· 8 months agoData from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut...
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
Zacks via Yahoo Finance· 5 months agoFor Immediate Release Chicago, IL – December 19, 2023 – Zacks.com announces the list of stocks...
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Zacks via Yahoo Finance· 1 year agoRegeneron's (REGN) share price rose after it reported data from a late-stage study showing that...
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 28, 2022 – Today, Zacks Equity Research discusses...
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for GSK (GSK). Shares have added about 6.7% in...
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
Zacks via Yahoo Finance· 1 year agoHere we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX),...
Glaxo (GSK) Down 1.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoIt has been about a month since the last earnings report for GSK (GSK). Shares have lost about 1.6%...
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
Zacks via Yahoo Finance· 8 months agoThe FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – May 20, 2022 – Today, Zacks Equity Research discusses Eli Lilly...